Active substances
Hydrocortisone + Miconazole
- SFDA 6
- NHS prices 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| DAKTACORT CREAM 20MG-GM | 2,1 %,% | Cream · Topical | 1 Tube | SAR 11.95 | NCE · Prescription | Johnson & Johnson Consumer NV/SA | Valid |
| MICOCORT CREAM | 2,1 %,% | Cream · Topical | 1 Tube | SAR 16.90 | Generic · Prescription | DEEF PHARMACEUTICAL INDUSTRIES | Valid |
| RESOLVE PLUS 1.0 CREAM | 2,1 %,% | Cream · Topical | 1 Tube | SAR 13.80 | Generic · Prescription | EGO PHARMACEUTICALS | Valid |
| CANDICORT CREAM | 2, 1 % | Cream · Topical | 1 Tube | SAR 6.45 | Generic · OTC | ARAB CENTER FOR PHARMACEUTICALS & CHEMICAL IND. CO. | Withdrawn by regulatory authority · Not Marketed |
| MICOVER- H CREAM | 2,0.2 %,% | Cream · Topical | 1 Tube | SAR 4.55 | Generic · Prescription | JORDAN RIVER PHARMACEUTICAL INDUSTRIES | Invalid · Not Marketed |
| MYCOHEAL HC CREAM | 2, 1 % | Cream · Topical | 1 Tube | SAR 7.20 | Generic · OTC | DAR ALDAWA | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ECZEMA; FUNGAL INFECTIONS OF THE GENITAL TRACT - CANDIDIASIS OF OTHER UROGENITAL SITES
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Hydrocortisone 1% / Miconazole 2% cream | £5.81 | 15 gram | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.